Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population

Cell Biochemistry and Function

Volumn 26, Issue 1, 2008, Pages 76-81

  Buzková, Helena ^a   Pechandová, Kristina ^a   Slanař, Ondřej ^a   Perlík, František ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cytochrome P 450 CYPD2D6; Czech population; Pharmacogenetics; Polymorphism

Indexed keywords

CYTOCHROME P450 2D6;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CZECH REPUBLIC; DRUG RESPONSE; FEMALE; GENE DUPLICATION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MALE; NORMAL HUMAN; PHARMACOGENETICS; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; CYTOCHROME P-450 CYP2D6; CZECH REPUBLIC; FEMALE; GENE FREQUENCY; GENETICS, POPULATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

MERLANGIUS MERLANGUS;

EID: 38549101363     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1402     Document Type: Article

References (24)

1. Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 2001; 58: 737-747.
2. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004; 25: 193-200.
3. Idle JR, Smith RL. Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. Drug Metab Rev 1979; 9: 301-317.
4. Bozina N, Granic P, Lalic Z, Tramisak I, Lovric M, Stavljenic-Rukavina A. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat Med J 2003; 44: 425-428.
5. Gaedigk A, Gotschall RR, Forbes NS, Simon SD. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 1999; 9: 669-682.
6. Meisel C, Gerloff T, Kirchheiner J, et al. Implications of pharmacogenetics for individualizing drug treatment and for study design. J Mol Med 2003; 81: 154-167.
7. Ciulla TA, Sklar RM, Hauser SL. A simple method for DNA purification from peripheral blood. Anal Biochem 1988; 174: 485-488.
8. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-295.
9. Steen VM, Andreassen OA, Daly AK, et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995; 5: 215-223.
10. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 1996; 392: 30-34.
11. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003; 59: 303-312.
12. Slanar O, Perlik F, Jirasek V. Phenotype of cytochrome P450 CYP2D6 in patients with familial adenomatous polyposis. Methods Find Exp Clin Pharmacol 2001; 23: 145-147.
13. Aynacioglu AS, Sachse C, Bozkurt A, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther 1999; 66: 185-192.
14. Shimizu T, Ochiai H, Asell F, et al. Bioinformatics research on inter-racial difference in drug metabolism I. analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2 C19. Drug Metab Pharmacokinet 2003; 18: 48-70.
15. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 89-104.
16. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Pelkonen O, Vainio H. PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Pharmacogenetics 1993; 3: 19-27.
17. Laforest L, Wikman H, Benhamou S, et al. CYP2D6 gene polymorphism in caucasian smokers: lung cancer susceptibility and phenotype-genotype relationships. Eur J Cancer 2000; 36: 1825-1832.
18. Tamminga WJ, Werner J, Oosterhuis B, de Zeeuw RA, de Leij LF, Jonkman JH. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur J Clin Pharmacol 2001; 57: 717-722.
19. Tefre T, Daly AK, Armstrong M, et al. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics 1994; 4: 47-57.
20. Niewinski P, Orzechowska-Juzwenko K, Hurkacz M, et al. CYP2D6 extensive, intermediate, and poor phenotypes and genotypes in a Polish population. Eur J Clin Pharmacol 2002; 58: 533-535.
21. Menoyo A, Del Rio E, Baiget M. Characterization of variant alleles of cytochrome CYP2D6 in a Spanish population. Cell Biochem Funct 2005; 24: 381-385.
22. Yamada H, Dahl ML, Lannfelt L, Viitanen M, Winblad B, Sjoqvist F. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur J Clin Pharmacol 1998; 54: 479-481.
23. Scordo MG, Caputi AP, D'Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004; 50: 195-200.
24. Dolzan V, Rudolf Z, Breskvar K. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls. Carcinogenesis 1995; 16: 2675-2678.